We are excited to participate in the MPS World Summit 2026, taking place May 26–29, 2026, in Washington, DC.

As a leading global event dedicated to microphysiological systems (MPS), this summit brings together experts across bioengineering, drug development, and regulatory science to advance next-generation human-relevant models. The program spans engineering of MPS platforms, disease modeling, applications in safety and efficacy, and regulatory adoption—key themes aligned with the growing importance of New Approach Methodologies (NAMs).

At this year’s meeting, Genoskin will present new data demonstrating how our ex vivo human skin platforms generate longitudinal, immunocompetent insights to support drug development.

Manon Scholaert¹,², Mathias Peries², Emilie Braun², Alexandra Ochando³, Emeline Pagès², Nicolas Gaudenzio¹,^2
1 Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 – CNRS UMR5051 – University Toulouse III, France, ² Genoskin SAS, Toulouse, France, ³ Genoskin Inc, Salem MA, USA

Abstract #169
Poster Session 1: Wednesday, May 27 | 9:30–11:00 AM

Microphysiological systems are transforming how human biology is modeled in vitro. Genoskin complements this landscape by providing native human tissue models with intact immune environments, enabling direct assessment of injection-site responses, integration with multi-omic and spatial biology tools, and improved prediction of clinical outcomes.

As regulatory momentum accelerates toward New Approach Methodologies (NAMs), our platforms offer ethical, reproducible, and human-relevant alternatives to animal models—aligned with evolving expectations for translational relevance in drug development.

We look forward to connecting with the global MPS community to share insights and explore new collaborations. Meet our team to learn how Genoskin can support your research with human-based solutions for immunology, safety, and translational science.